| FERRING INTERNATIONAL CENTER S.A. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120015036 | Process For The Manufacture Of A Pharmaceutical Product - A process for the preparation of a pharmaceutical composition comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulphate and, optionally, saccharin sodium and/or orange flavor; products, intermediate products, and uses thereof. | 01-19-2012 |
| 20110105398 | RECOMBINANT FSH INCLUDING ALPHA 2,3- AND ALPHA 2,6-SAILYLATIO - Preparations including recombinant FSH (rFSH). | 05-05-2011 |
| 20110104285 | PROCESS FOR THE MANUFACTURE OF A PHARMACEUTICAL PRODUCT - A process for the preparation of a pharmaceutical composition comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulphate and, optionally, saccharin sodium and/or orange flavour; products, intermediate products, and uses thereof. | 05-05-2011 |
| 20110015268 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising a docusate; an osmotic laxative; and a benzoate. | 01-20-2011 |
| 20100113499 | MEDICAMENT FOR THE TREATMENT OF ENDOMETRIOSIS - The use of a dopamine agonist in the manufacture of a medicament for the treatment or prevention of endometriosis. | 05-06-2010 |
| 20080318847 | Use of Antagonist of Oxytocin and/or Vasopressin in Assisted Reproduction - The present invention relates to the use of antagonists of oxytocin, antagonists of oxytocin and vasopressin, or antagonists of vasopressin, or their pharmaceutically accepted salts, or their combinations with other drugs for the manufacture of a medicament which main profile of action is inhibition of oxytocin and/or vasopressin receptors in non-pregnant uterus of mammals, that results in improvement of uterine receptivity in embryo transfer. It further relates to the application of these substances for the manufacture of a medicament for regulating the uterine contractile activity in cases of artificial insemination. | 12-25-2008 |
| 20080293693 | Treatment or Prevention of Ovarian Hyperstimulation Syndrome (Ohss) Using a Dopamine Agonist - Disclosed herein is a method for preventing ovarian hyperstimulation syndrome in a subject by administering an effective amount of a dopamine agonist in a pharmaceutically acceptable carrier. Also disclosed herein is a method for treating ovarian hyperstimulation syndrome by administering an effective amount of a dopamine agonist in a pharmaceutically acceptable carrier. | 11-27-2008 |
